Global Fund launches key targeted funding round
This article was originally published in Clinica
The Global Fund to Fight AIDS, Tuberculosis and Malaria today launched the sixth funding round, with a call for proposals and a reminder of the global challenges set for improving care of these diseases. These include achieving universal access to AIDS treatment and prevention by 2010, and halving deaths from tuberculosis and malaria by 2015.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.